Paul Sherwin
Overview
Explore the profile of Paul Sherwin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
327
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hattori N, Sherwin P, Farrar G
J Alzheimers Dis Rep
. 2020 Jul;
4(1):165-174.
PMID: 32715277
Background: Brain amyloid is a neuropathological hallmark of Alzheimer's disease (AD). By visualizing brain amyloid, positron emission tomography (PET) may influence the diagnostic assessment and management of patients with cognitive...
2.
Ikonomovic M, Buckley C, Heurling K, Sherwin P, Jones P, Zanette M, et al.
Acta Neuropathol Commun
. 2016 Dec;
4(1):130.
PMID: 27955679
In vivo imaging of fibrillar β-amyloid deposits may assist clinical diagnosis of Alzheimer's disease (AD), aid treatment selection for patients, assist clinical trials of therapeutic drugs through subject selection, and...
3.
Thurfjell L, Lilja J, Lundqvist R, Buckley C, Smith A, Vandenberghe R, et al.
J Nucl Med
. 2014 Aug;
55(10):1623-8.
PMID: 25146124
Unlabelled: Clinical trials of the PET amyloid imaging agent (18)F-flutemetamol have used visual assessment to classify PET scans as negative or positive for brain amyloid. However, quantification provides additional information...
4.
Grosset D, Tatsch K, Oertel W, Tolosa E, Bajaj N, Kupsch A, et al.
J Nucl Med
. 2014 Jun;
55(8):1281-7.
PMID: 24947061
Ioflupane is an analog of cocaine that binds reversibly with high affinity to the dopamine transporter (DaT) protein, a marker for presynaptic terminals in dopaminergic nigrostriatal neurons. Ioflupane (123)I Injection...
5.
Rinne J, Frantzen J, Leinonen V, Lonnrot K, Laakso A, Virtanen K, et al.
Neurodegener Dis
. 2013 Dec;
13(4):237-45.
PMID: 24296542
Unlabelled: BACKGOUND/OBJECTIVE: To determine the level of association between uptake of the amyloid positron emission tomography (PET) imaging agent [(18)F]flutemetamol and the level of amyloid-β measured by immunohistochemical and histochemical...
6.
Main M, Grayburn P, Lang R, Goldman J, Gibson C, Sherwin P, et al.
Am J Cardiol
. 2013 Sep;
112(10):1657-61.
PMID: 24041914
Ultrasound contrast agent safety has received recent attention based on reports of associated serious adverse events. The US Food and Drug Administration requested this postmarketing study of the effects of...
7.
Wong D, Moghekar A, Rigamonti D, Brasic J, Rousset O, Willis W, et al.
Mol Imaging Biol
. 2012 Aug;
15(2):230-7.
PMID: 22878921
Purpose: The primary objectives of this study were to assess the safety of [(18)F]flutemetamol injection and determine the level of association between the quantitative estimates of brain uptake of [(18)F]flutemetamol...
8.
Kupsch A, Bajaj N, Weiland F, Tartaglione A, Klutmann S, Copp R, et al.
Neurodegener Dis
. 2012 May;
11(1):22-32.
PMID: 22571977
Background: An accurate diagnosis is important for timely and adequate treatment in patients with clinically uncertain parkinsonian syndrome (CUPS). Objective: The objective of this study was to assess safety and...
9.
Kupsch A, Bajaj N, Weiland F, Tartaglione A, Klutmann S, Buitendyk M, et al.
J Neurol Neurosurg Psychiatry
. 2012 Apr;
83(6):620-8.
PMID: 22492213
Background: This study assessed the impact of DaTscan on clinical management, diagnosis, confidence of diagnosis (CoD), quality of life (QoL), health resource use (HRU) and safety during a 1-year follow-up...
10.
Wolk D, Grachev I, Buckley C, Kazi H, Grady M, Trojanowski J, et al.
Arch Neurol
. 2011 Jul;
68(11):1398-403.
PMID: 21747004
Objective: To determine the correspondence of in vivo quantitative estimates of brain uptake of fluorine 18-labeled flutemetamol with immunohistochemical estimates of amyloid levels in patients who underwent previous biopsy. Design:...